Cardiology Groups Stand by Embattled Diabetes Drug

MedPage Today -- There's not good enough reason to pick pioglitazone (Actos) over rosiglitazone (Avandia) despite controversy on cardiac safety, according to the American Heart Association and American College of Cardiology.